Frontiers in Pharmacology (Aug 2022)
TMAO as a potential biomarker and therapeutic target for chronic kidney disease: A review
- Ye Zixin,
- Ye Zixin,
- Ye Zixin,
- Ye Zixin,
- Chen Lulu,
- Chen Lulu,
- Zeng Xiangchang,
- Zeng Xiangchang,
- Zeng Xiangchang,
- Zeng Xiangchang,
- Fang Qing,
- Zheng Binjie,
- Zheng Binjie,
- Zheng Binjie,
- Zheng Binjie,
- Luo Chunyang,
- Rao Tai,
- Rao Tai,
- Rao Tai,
- Rao Tai,
- Ouyang Dongsheng,
- Ouyang Dongsheng,
- Ouyang Dongsheng,
- Ouyang Dongsheng,
- Ouyang Dongsheng
Affiliations
- Ye Zixin
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Ye Zixin
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, China
- Ye Zixin
- Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China
- Ye Zixin
- National Clinical Research Center for Geriatric Disorders, Changsha, China
- Chen Lulu
- Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha, China
- Chen Lulu
- Department of Clinical Pharmacy, Affiliated Hospital of Xiangnan University, Chenzhou, China
- Zeng Xiangchang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Zeng Xiangchang
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, China
- Zeng Xiangchang
- Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China
- Zeng Xiangchang
- National Clinical Research Center for Geriatric Disorders, Changsha, China
- Fang Qing
- Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha, China
- Zheng Binjie
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Zheng Binjie
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, China
- Zheng Binjie
- Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China
- Zheng Binjie
- National Clinical Research Center for Geriatric Disorders, Changsha, China
- Luo Chunyang
- Department of Clinical Pharmacy, Affiliated Hospital of Xiangnan University, Chenzhou, China
- Rao Tai
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Rao Tai
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, China
- Rao Tai
- Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China
- Rao Tai
- National Clinical Research Center for Geriatric Disorders, Changsha, China
- Ouyang Dongsheng
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
- Ouyang Dongsheng
- Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, China
- Ouyang Dongsheng
- Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China
- Ouyang Dongsheng
- National Clinical Research Center for Geriatric Disorders, Changsha, China
- Ouyang Dongsheng
- Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha, China
- DOI
- https://doi.org/10.3389/fphar.2022.929262
- Journal volume & issue
-
Vol. 13
Abstract
The gut microbiota and its metabolites have become a hotspot of recent research. Trimethylamine N-oxide (TMAO) metabolized by the gut microbiota is closely related to many diseases such as cardiovascular disease, chronic kidney disease, type 2 diabetes, etc. Chronic kidney disease (CKD) is an important contributor to morbidity and mortality from non-communicable diseases. Recently, increasing focus has been put on the role of TMAO in the development and progress of chronic kidney disease. The level of TMAO in patients with chronic kidney disease is significantly increased, and a high level of TMAO deteriorates chronic kidney disease. This article describes the relationship between TMAO and chronic kidney disease and the research progress of drugs targeted TMAO, providing a reference for the development of anti-chronic kidney disease drugs targeted TMAO.
Keywords
- trimethylamine N-oxide
- chronic kidney disease
- gut microbiota
- targeted TMAO drugs
- mechanism
- treatment
